How effective are dabrafenib and trametinib in lung cancer?

Dabrafenib and trametinib are not the first choice drugs in the treatment of lung cancer. Although BRAF V600mutations have a certain incidence in lung cancer, BRAF V600mutations in lung cancer are less common than in melanoma. Therefore, the efficacy of dabrafenib and trametinib in the treatment of lung cancer is relatively limited. For lung cancer patients with BRAF V600 mutations, current treatments mainly focus on other treatments, such as targeted therapy, chemotherapy, immunotherapy, etc. When selecting a treatment plan, doctors will conduct a comprehensive assessment based on the patient's condition, genotype, and other relevant factors, and develop the most appropriate treatment plan. Therefore, dabrafenib and trametinib are relatively rarely used in the treatment of lung cancer, and clinical data and efficacy need to be further studied and confirmed.